Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Brokerages

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $42.4286.

DMRA has been the subject of a number of analyst reports. TD Cowen initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They issued a “buy” rating for the company. HC Wainwright started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 11th. They issued a “buy” rating and a $45.00 price objective for the company. Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. Finally, Wedbush reiterated an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, June 12th.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors have recently made changes to their positions in DMRA. Ikarian Capital LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $6,574,000. Janus Henderson Group PLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $40,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $2,204,000. Jain Global LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $2,774,000. Finally, Remedium Capital Partners LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $2,772,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Trading Up 1.5%

Shares of NASDAQ:DMRA traded up $0.46 during mid-day trading on Tuesday, reaching $30.26. The stock had a trading volume of 138,343 shares, compared to its average volume of 372,567. The company has a market cap of $1.86 billion, a P/E ratio of -5.42 and a beta of 1.46. The business’s 50 day moving average price is $23.96 and its 200 day moving average price is $25.43. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.